Cyntellect

Executive Management
Manfred R. Koller, Ph.D., the Company’s founding executive, currently serves as its President and Chief Technology Officer (CTO). Dr. Koller was named President and CTO effective December 2004. He also served as Acting President and CTO from May 2004 to December 2004, and Vice President of R&D and Chief Operating Officer from June 2000 to May 2004. Prior to joining the Company in August 1998, Dr. Koller was Senior Group Leader, Product Development at Advanced Tissue Sciences. Prior to joining Advanced Tissue Sciences Dr. Koller served in several research and engineering leadership positions at Aastrom Biosciences (NASDAQ: ASTM), and prior to that, at Baxter International (NYSE: BAX). He holds a Ph.D. degree in Biochemical Engineering and a B.S. degree in Chemical Engineering, both from Northwestern University.

Jim Linton, Ph.D., M.B.A., joined the Company in July 2004 as its Chief Business Officer and Head of Business Development. Prior to joining the Company, Dr. Linton was the Vice President of Business Affairs for Protometrix, Inc. from March 2003 to July 2004. He served as Vice President of Business Development at Genicon Sciences from November 1999 to November 2002. He holds a Ph.D. degree in molecular genetics from Emory University, an M.B.A. with emphasis in technology marketing from the University of California, Davis and a B.S. degree in Biological Sciences from Muhlenberg College.

David W. Nassif, J.D., joined the Company as its Interim Chief Financial Officer in September 2006. From 2002 to 2006, he was the Chief Financial Officer and Senior Vice President of Global Licensing of Amphastar Pharmaceuticals, Inc., a privately-held, generic and specialty pharmaceutical company. From 2001 to 2002, Mr. Nassif was a principal in Strategic Consulting Services, providing capital raising, mergers and acquisitions, licensing, and investor relations services to various public and private life science and technology companies, including Amphastar. From 2000 to 2001, Mr. Nassif was the Senior Vice President, Chief Financial Officer, Treasurer, and Secretary of RealAge, Inc., a privately held health care database information marketing company. From 1993 to 1999, Mr. Nassif held various positions with Cypros Pharmaceutical Corporation, an AMEX-listed specialty pharmaceutical company, culminating in the position of Senior Vice President, Chief Financial Officer, Treasurer and Secretary. Mr. Nassif received a B.Sc. in finance and management information systems from the University of Virginia and a J.D. from the University of Virginia School of Law.

Board of Directors
Bernhard O. Palsson, Ph.D., the Company’s founder, has served as the Company’s Chairman of the Board and as a director since the Company’s inception in 1998. Dr. Palsson is professor of Bioengineering and Adjunct Professor Medicine at the University of California, San Diego. Dr. Palsson co-founded Aastrom Biosciences (NASDAQ: ASTM) in 1988, where he served as the Vice President of Developmental Research for two years. Dr. Palsson is also the founder of Genomatica, a company that is focused on in silico biology. Professor Palsson is a member of the National Academy of Engineering and holds a Ph.D. degree in Bioengineering from the University of Wisconsin.

Fridrik Johannsson, CPA, joined as a member of the Company’s Board of Directors in April 2006. Mr. Johannsson is the Chairman and major shareholder of TM Software, an international software company serving various markets. He was the President and CEO of Skandia in Iceland, an insurance and asset management and securities brokerage firm, from May 1989 to October 1996 and Managing Director of Burdaras Investments from October 1996 to March 2004 and President and CEO of Burdaras hf, a listed investment company in Iceland from March 2004 to September 2005. Mr. Johannsson also serves as the Chairman of the Board of the Icelandic Stock Exchange. Mr. Johannsson currently serves on the boards of directors for Marel hf, Softis hf, Verdbrefaskraning Islands hf and Iceland Genomic Ventures Holding. During the last 5 years, Mr. Johannsson has served on the board of directors of Alfesca hf, Thróunarfélag Islands hf, Eimskipafélag Islands hf, Haraldur Böðvarsson & Co hf, Skagstrendingur hf, Flow Matrix Inc., Urður Verðandi Skuld hf (UVS) and Og Vodafone hf. He received a Cand oecon degree from the University of Iceland and is a certified public accountant.

S. Wayne Kay, M.B.A., joined as a member of the Company’s Board of Directors in April 2006. Mr. Kay serves as an executive advisor to several medical device and life science companies in the United States. From January 2001 to October 2004, he was President, Chief Executive Officer and a director of Quidel Corporation. Prior to joining Quidel, Mr. Kay served as President, Chief Executive Officer and director of the Health Industry Distributors Association, and prior to that he was President, Chief Executive Officer, and director of Enzymatics, Inc. Mr. Kay serves on the boards of directors of iMedical Devices, Inc., the Health Industry Distributors Association, Taking Control of Your Diabetes and the Board of Trustees of Boys & Girls Clubs of America. He holds an M.B.A. degree from Pepperdine University and a B.S. degree in Business Administration from the University of San Francisco.

Manfred R. Koller, Ph.D., joined as a member of the Company's Board of Directors in August 2006. Dr. Koller is the Company's founding executive, currently serves as its President and Chief Technology Officer (CTO). See "Executive Management"

Tina S. Nova, Ph.D., joined as a member of the Company’s Board of Directors in December 2004, and was appointed lead independent director in February 2006. Dr. Nova is President, Chief Executive Officer, co-founder and a director of Genoptix, Inc., since March 2000. Dr. Nova was a co-founder of Nanogen, Inc., where she served as Chief Operating Officer and President from 1994 to January 2000. She serves on the advisory board of University of California, Irvine Division of Biological Sciences. She is also on the Board of Trustees of the University of San Diego and is the life science sector representative to the Independent Citizen’s Oversight Committee overseeing the implementation of the California stem cell initiative, Proposition 71. She is also a director of Arena Pharmaceuticals, Inc. and Heska Corporation. She holds a Ph.D. degree in Biochemistry from the University of California, Riverside and a B.S., degree in Biological Sciences from the University of California, Irvine.